Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.64 +4.5%	$1.48	$1.01 ▼ $3.31	$465.22M	1.07	796,286 shs	456,830 shs
KMDA Kamada	$7.35 +0.7%	$7.46	$5.17 ▼ $9.15	$422.66M	0.93	49,571 shs	25,607 shs
KOD Kodiak Sciences	$10.57 +5.3%	$5.58	$1.92 ▼ $11.60	$558.33M	2.41	715,401 shs	1.59 million shs
TNYA Tenaya Therapeutics	$1.16 +22.5%	$0.70	$0.36 ▼ $4.01	$189.05M	3.01	2.56 million shs	9.05 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	0.00%	+17.14%	+10.07%	+27.63%	-36.68%
KMDA Kamada	0.00%	+3.23%	-1.08%	+5.91%	+37.90%
KOD Kodiak Sciences	0.00%	+33.80%	+103.66%	+202.00%	+314.51%
TNYA Tenaya Therapeutics	0.00%	+73.42%	+33.93%	+158.01%	-59.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	2.4514 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
KMDA Kamada	4.6352 of 5 stars	3.3	5.0	0.0	3.2	1.7	4.4
KOD Kodiak Sciences	2.4327 of 5 stars	1.0	1.0	4.6	2.5	3.3	0.0
TNYA Tenaya Therapeutics	2.8101 of 5 stars	3.5	1.0	0.0	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	3.00	Buy	$4.57	178.75% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	76.87% Upside
KOD Kodiak Sciences	2.00	Hold	$11.25	6.43% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	438.79% Upside

Current Analyst Ratings Breakdown

Latest TNYA, KOD, KMDA, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00
8/7/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.31 per share	N/A
KMDA Kamada	$160.95M	2.63	$0.49 per share	14.95	$4.52 per share	1.63
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$1.33 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	N/A
KMDA Kamada	$14.46M	$0.34	21.62	22.97	0.78	11.22%	7.41%	5.18%	N/A
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A
TNYA Tenaya Therapeutics	-$111.13M	-$0.96	N/A	N/A	N/A	N/A	-93.83%	-75.66%	11/5/2025 (Estimated)

Latest TNYA, KOD, KMDA, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
8/6/2025	Q2 2025	TNYA Tenaya Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	11.03	12.35
KMDA Kamada	N/A	4.00	1.93
KOD Kodiak Sciences	N/A	3.48	4.62
TNYA Tenaya Therapeutics	N/A	6.00	6.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
KMDA Kamada	20.38%
KOD Kodiak Sciences	89.06%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.40%
KMDA Kamada	36.10%
KOD Kodiak Sciences	45.90%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.67 million	242.82 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable
TNYA Tenaya Therapeutics	110	162.98 million	83.69 million	Optionable

TNYA, KOD, KMDA, and ERAS Headlines

Recent News About These Companies

Tenaya Therapeutics Reports Q2 2025 Financial Results

August 14 at 12:57 AM | tipranks.com

What is Leerink Partnrs' Forecast for TNYA FY2025 Earnings?

August 12, 2025 | americanbankingnews.com

William Blair Issues Optimistic Estimate for TNYA Earnings

August 12, 2025 | americanbankingnews.com

What is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?

August 11, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Upgraded by Wall Street Zen to "Hold" Rating

August 11, 2025 | americanbankingnews.com

Q3 EPS Estimate for Tenaya Therapeutics Lifted by Analyst

August 11, 2025 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Hold

August 10, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at Chardan Capital

August 8, 2025 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 8, 2025 | globenewswire.com

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

August 7, 2025 | msn.com

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Tenaya (TNYA) Q2 Loss Narrows 59%

August 7, 2025 | fool.com

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025 | globenewswire.com

Equities Analysts Offer Predictions for TNYA Q1 Earnings

August 4, 2025 | marketbeat.com

Lifesci Capital Issues Negative Outlook for TNYA Earnings

August 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from Analysts

August 1, 2025 | marketbeat.com

Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies

July 30, 2025 | investing.com

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

July 30, 2025 | globenewswire.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, KOD, KMDA, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

$1.64 +0.07 (+4.46%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.66 +0.02 (+0.91%)

As of 08/15/2025 07:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Kamada NASDAQ:KMDA

$7.35 +0.05 (+0.68%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.38 +0.03 (+0.41%)

As of 08/15/2025 06:35 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kodiak Sciences NASDAQ:KOD

$10.57 +0.53 (+5.28%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.11 -0.46 (-4.34%)

As of 08/15/2025 07:20 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Tenaya Therapeutics NASDAQ:TNYA

$1.16 +0.21 (+22.51%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.16 0.00 (0.00%)

As of 08/15/2025 07:59 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time